Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer

医学 免疫疗法 肺癌 癌症免疫疗法 癌症 肿瘤科 癌症研究 免疫学 内科学
作者
Tina Cascone,Jared J. Fradette,Monika Pradhan,Don L. Gibbons
出处
期刊:Cold Spring Harbor Perspectives in Medicine [Cold Spring Harbor Laboratory Press]
卷期号:12 (5): a037895-a037895 被引量:73
标识
DOI:10.1101/cshperspect.a037895
摘要

Historically, non-small-cell lung cancer (NSCLC) has been regarded as a nonimmunogenic tumor; however, recent studies have shown that NSCLCs are among the most responsive cancers to monoclonal antibody immune checkpoint inhibitors (ICIs). ICIs have dramatically improved clinical outcomes for a subset of patients (∼20%) with locally advanced and metastatic NSCLC, and they have also demonstrated promise as neoadjuvant therapy for early-stage resectable disease. Nevertheless, the majority of patients with NSCLC are refractory to ICIs for reasons that are poorly understood. Thus, major questions are: how do we initially identify the patients most likely to derive significant clinical benefit from these therapies; how can we increase the number of patients benefiting; what are the mechanisms of primary and acquired resistance to immune-based therapies; are there additional immune checkpoints besides PD-1/PD-L1 and CTLA-4 that can be targeted to provide greater clinical benefit to patients; and how do we best combine ICI therapy with surgery, radiotherapy, chemotherapy, and targeted therapy? To answer these questions, we need to deploy the latest technologies to study tumors and their microenvironment and how they interact with components of the innate and adaptive immune systems. There is also a need for new preclinical model systems to investigate the molecular mechanisms of resistance to treatment and identify novel therapeutic targets. Recent advances in technology are beginning to shed new light on the immune landscape of NSCLC that may uncover biomarkers of response and maximize the clinical benefit of immune-based therapies. Identification of the mechanisms of resistance should lead to the identification of novel targets and the generation of new therapeutic strategies that improve outcomes for a greater number of patients. In the sections below, we discuss the results of studies examining the immune microenvironment in NSCLC, summarize the clinical experience with immunotherapy for NSCLC, and review candidate biomarkers of response to these agents in NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zeng发布了新的文献求助10
刚刚
研友_841KWL完成签到,获得积分10
刚刚
刚刚
stopray完成签到,获得积分20
刚刚
momo完成签到,获得积分10
刚刚
zyf发布了新的文献求助10
1秒前
赘婿的应助被dlc采纳,获得10
1秒前
二闲完成签到,获得积分10
1秒前
英俊的铭的应助被Crush采纳,获得10
1秒前
1秒前
帅子完成签到,获得积分10
2秒前
刘刘完成签到,获得积分10
2秒前
传奇3的应助被kurumi采纳,获得10
2秒前
CipherSage的应助被111采纳,获得10
2秒前
3秒前
bkagyin的应助被背后白柏采纳,获得10
3秒前
源宥冰完成签到,获得积分10
3秒前
忘记考红薯了完成签到,获得积分10
3秒前
孔德颍完成签到,获得积分10
3秒前
lzh完成签到,获得积分10
3秒前
attt完成签到 ,获得积分10
3秒前
stopray发布了新的文献求助10
3秒前
3秒前
parny完成签到 ,获得积分10
4秒前
4秒前
4秒前
QDU的应助被NICE采纳,获得10
4秒前
4秒前
石大李克的应助被ale采纳,获得10
4秒前
Hello的应助被爱听歌的八宝粥采纳,获得10
4秒前
冷傲雨竹完成签到,获得积分10
5秒前
wngaoran完成签到,获得积分10
5秒前
1101592875发布了新的文献求助30
6秒前
6秒前
6秒前
慧慧完成签到,获得积分10
6秒前
题西林壁完成签到,获得积分10
6秒前
molihuakai的应助被GX采纳,获得10
6秒前
7秒前
观的完成签到,获得积分20
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287